INT30382

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1985
Last Reported 2010
Negated 2
Speculated 0
Reported most in Abstract
Documents 21
Total Number 23
Disease Relevance 12.06
Pain Relevance 8.19

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

aging (Ednra) plasma membrane (Ednra) signal transducer activity (Ednra)
Anatomy Link Frequency
NACC 2
vasculature 2
endothelium 2
coronary artery 1
endocrine system 1
Ednra (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antagonist 65 100.00 Very High Very High Very High
anesthesia 11 99.80 Very High Very High Very High
ischemia 40 99.48 Very High Very High Very High
Nucleus accumbens 94 99.44 Very High Very High Very High
Ventral tegmentum 23 99.10 Very High Very High Very High
Brush evoked pain 9 98.28 Very High Very High Very High
Inflammation 24 98.08 Very High Very High Very High
Kinase C 80 97.88 Very High Very High Very High
opioid receptor 18 97.48 Very High Very High Very High
tolerance 4 97.40 Very High Very High Very High
Disease Link Frequency Relevance Heat
Hypertension 21 99.96 Very High Very High Very High
Cv General 4 Under Development 37 99.84 Very High Very High Very High
Pressure And Volume Under Development 58 99.82 Very High Very High Very High
Middle Cerebral Artery Infarction 30 99.36 Very High Very High Very High
Pulmonary Hypertension 156 99.20 Very High Very High Very High
Raynauds Disease 1 98.48 Very High Very High Very High
Neuropathic Pain 11 98.28 Very High Very High Very High
Reperfusion Injury 1 98.24 Very High Very High Very High
INFLAMMATION 27 98.08 Very High Very High Very High
Impaired Glucose Tolerance 1 97.72 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These results, together with the previous finding that BQ-123, an ETA-specific receptor antagonist, inhibits the ductal constriction induced by oxygen in vitro [Coceani et al., 1992], indicate that the ETA receptor plays a significant role in the indomethacin- or methylene blue-induced DA constriction as well as in the spontaneous DA constriction after birth, and also indicate that the inhibition of ETA receptor by TAK-044 was more easily achieved in fetuses than in neonates.
Negative_regulation (inhibition) of ETA receptor associated with antagonist
1) Confidence 0.42 Published 2000 Journal J. Vet. Med. Sci. Section Abstract Doc Link 10852399 Disease Relevance 0 Pain Relevance 0.08
These results indicate that the selective blockade of endothelin ET(A) receptors results in an attenuation of tactile allodynia in the streptozotocin-treated rat.
Negative_regulation (blockade) of endothelin ET associated with brush evoked pain
2) Confidence 0.39 Published 2000 Journal Eur. J. Pharmacol. Section Abstract Doc Link 10657544 Disease Relevance 0.76 Pain Relevance 0.93
Selective blockade of endothelin receptor subtypes on systemic and renal vascular responses to endothelin-1 and IRL1620, a selective endothelin ETB-receptor agonist, in anesthetized rats.
Negative_regulation (blockade) of endothelin receptor associated with anesthesia and agonist
3) Confidence 0.37 Published 1996 Journal Jpn. J. Pharmacol. Section Title Doc Link 8854203 Disease Relevance 0.12 Pain Relevance 0.28
Improvement of postischemic hepatic microcirculation after endothelinA receptor blockade--endothelin antagonism influences platelet-endothelium interactions.
Negative_regulation (blockade) of endothelinA receptor in endothelium
4) Confidence 0.27 Published 2005 Journal J. Gastrointest. Surg. Section Title Doc Link 15694814 Disease Relevance 0.57 Pain Relevance 0.29
(Figure 1B); consequently, 4 enantiomers that are derived from chiral separation share beneficial effects on the pulmonary hypertension through suppressing the ET receptor.12 Besides, a new endothelin receptor antagonist, CPU0213 (Figure 1C), which suppresses both the ETA and ETB, referred as a nonselective (or dual) endothelin receptor antagonist which is effective in suppressing upregulated ET receptors resulting in relieving pulmonary arterial hypertension and vascular abnormalities in diabetic vasculature.1,13

Vascular abnormalities and oxidative stress

Negative_regulation (suppressing) of ET receptor in vasculature associated with stress, pulmonary hypertension, pressure and volume under development, diabetes mellitus, congenital anomalies and antagonist
5) Confidence 0.24 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941789 Disease Relevance 1.39 Pain Relevance 0.21
(Figure 1B); consequently, 4 enantiomers that are derived from chiral separation share beneficial effects on the pulmonary hypertension through suppressing the ET receptor.12 Besides, a new endothelin receptor antagonist, CPU0213 (Figure 1C), which suppresses both the ETA and ETB, referred as a nonselective (or dual) endothelin receptor antagonist which is effective in suppressing upregulated ET receptors resulting in relieving pulmonary arterial hypertension and vascular abnormalities in diabetic vasculature.1,13

Vascular abnormalities and oxidative stress

Negative_regulation (suppresses) of ETA in vasculature associated with stress, pulmonary hypertension, pressure and volume under development, diabetes mellitus, congenital anomalies and antagonist
6) Confidence 0.24 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941789 Disease Relevance 1.41 Pain Relevance 0.21
It could be shown for the first time that endothelin receptor blockade also influences platelet-endothelium interactions.
Negative_regulation (blockade) of endothelin receptor in endothelium
7) Confidence 0.24 Published 2004 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 15838253 Disease Relevance 0.31 Pain Relevance 0.27
ETA appears to be at the center in modulating the vascular activity, and an upregulated ETA has been found under multiple conditions: congestive heart failure, hypertension, atherosclerosis, endothelial dysfunction, coronary artery diseases, renal failure, cerebrovascular disease, pulmonary arterial hypertension, and sepsis.3 Interestingly, some substances and prescriptions in Traditional Chinese Medicine (TCM) may be effective in reversing endothelial insults by suppressing the activated ETA, such as quercetin, isorhamnetin, or chelerythrine (protein kinase C (PKC) inhibitor), a modified rehmannia decoction (Liu-wei-di-huang decoction), and total triterpene acids isolated from corni fructus.1,4,5
Negative_regulation (suppressing) of ETA in coronary artery associated with pressure and volume under development, heart rate under development, coronary artery disease, renal failure, increased venous pressure under development, sepsis, cerebrovascular disease, kinase c and pulmonary hypertension
8) Confidence 0.21 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941789 Disease Relevance 1.94 Pain Relevance 0.13
ETA receptor blockade may represent a new therapeutic principle for improving glucose tolerance in Type II diabetes and could be beneficial in alleviating or preventing hyperglycaemia-related secondary complications in this condition.
Negative_regulation (blockade) of ETA receptor associated with diabetes mellitus, tolerance and impaired glucose tolerance
9) Confidence 0.20 Published 2002 Journal Clin. Sci. Section Abstract Doc Link 12193138 Disease Relevance 0.39 Pain Relevance 0.17
The effect of endothelin receptor inhibition in cerebral ischemia has been widely studied, but the results have not been conclusive [24-26].
Negative_regulation (inhibition) of endothelin receptor associated with cv general 4 under development and ischemia
10) Confidence 0.20 Published 2007 Journal BMC Neurosci Section Body Doc Link PMC1770924 Disease Relevance 0.63 Pain Relevance 0.36
Therefore a specific ET receptor blocker may not be the most useful way of treatment, but rather an inhibitor of the pathways leading to the receptor changes.
Negative_regulation (blocker) of ET receptor
11) Confidence 0.19 Published 2007 Journal BMC Neurosci Section Body Doc Link PMC1770924 Disease Relevance 0.56 Pain Relevance 0.28
During locomotion, HPCtheta was attenuated, but not eliminated, in rats with KA or SAP lesions.
Neg (not) Negative_regulation (attenuated) of HPCtheta
12) Confidence 0.17 Published 2005 Journal Hippocampus Section Abstract Doc Link 15630696 Disease Relevance 0 Pain Relevance 0.33
During locomotion, HPCtheta was attenuated, but not eliminated, in rats with KA or SAP lesions.
Neg (not) Negative_regulation (eliminated) of HPCtheta
13) Confidence 0.17 Published 2005 Journal Hippocampus Section Abstract Doc Link 15630696 Disease Relevance 0 Pain Relevance 0.34
Therefore, inhibition of the endothelin ET(B) receptor could be beneficial on controlling inflammatory hypernociception of diseases in which IL-18 plays a role in their pathogenesis.
Negative_regulation (inhibition) of ET associated with inflammation and disease
14) Confidence 0.13 Published 2004 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 15075358 Disease Relevance 0.33 Pain Relevance 0.40
Possible pharmacologic therapies for the prevention of DU include vasodilating agents to treat Raynaud phenomenon, statins, and oral agents used in the treatment of pulmonary hypertension (endothelin receptor antagonists, phosphodiesterase-5 inhibitors).
Negative_regulation (inhibitors) of endothelin receptor associated with raynauds disease, antagonist, hypertension and ulcers
15) Confidence 0.12 Published 2007 Journal J Dtsch Dermatol Ges Section Abstract Doc Link 17537038 Disease Relevance 1.58 Pain Relevance 0.23
Bosentan (Ro 47-0203) is a competitive antagonist of both ETA and ETB.
Negative_regulation (antagonist) of ETA associated with antagonist
16) Confidence 0.10 Published 2006 Journal World J Emerg Surg Section Body Doc Link PMC1764411 Disease Relevance 1.06 Pain Relevance 0.22
Oral sildenafil, a PDE5 inhibitor, prevented (in a study in which sildenafil was given 1 day after MCT) and reversed (in a study in which sildenafil was given 3 weeks after MCT) the development of PAH in MCT-treated rats, associated with a reduction in the ETA-receptor density in SMCs of pulmonary small arteries (diameter < 100??
Negative_regulation (reduction) of ETA-receptor associated with pulmonary hypertension
17) Confidence 0.10 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 0.95 Pain Relevance 0.24
Unilateral (40, 60 microg) and bilateral (10 microg) VTA infusions were also observed to selectively reduced EtOH responding; however, greater nalmefene doses were required and the magnitude of suppression on EtOH responding was markedly less compared with the NACC.
Negative_regulation (reduced) of EtOH in NACC associated with nucleus accumbens and ventral tegmentum
18) Confidence 0.04 Published 2004 Journal Neuropsychopharmacology Section Abstract Doc Link 14603266 Disease Relevance 0 Pain Relevance 0.81
In contrast, intrahippocampal infusions dose dependently suppressed EtOH- and saccharin-maintained responding over a range of doses (1-20 microg).
Negative_regulation (suppressed) of EtOH
19) Confidence 0.03 Published 2004 Journal Neuropsychopharmacology Section Abstract Doc Link 14603266 Disease Relevance 0 Pain Relevance 0.62
These changes in numbers and binding properties of alpha 1-adrenoreceptors probably account for the decreased NE sensitization of the ATPase to EtOH inhibition in preparations from EtOH-tolerant rats.
Negative_regulation (inhibition) of EtOH
20) Confidence 0.03 Published 1985 Journal Can. J. Physiol. Pharmacol. Section Abstract Doc Link 2864993 Disease Relevance 0 Pain Relevance 0.29

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox